Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 93.60M P/E - EPS this Y 74.90% Ern Qtrly Grth -
Income -72.92M Forward P/E -1.34 EPS next Y -72.30% 50D Avg Chg -1.00%
Sales 21.84M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 0.92 EPS next 5Y - 52W High Chg -29.00%
Recommedations 3.00 Quick Ratio 2.88 Shares Outstanding 22.76M 52W Low Chg 41.00%
Insider Own 12.21% ROA -29.23% Shares Float 117.51M Beta 0.55
Inst Own 103.60% ROE -71.51% Shares Shorted/Prior 31.47K/41K Price 5.08
Gross Margin -264.11% Profit Margin - Avg. Volume 38,522 Target Price 16.00
Oper. Margin -342.83% Earnings Date Mar 5 Volume 9,890 Change 2.63%
About Orchard Therapeutics plc

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

ORTX Chatroom

User Image Stock_Titan Posted - 4 days ago

$ORTX Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 https://www.stocktitan.net/news/ORTX/orchard-therapeutics-announces-multiple-presentations-at-asgct-gwjwbdknbfsm.html

User Image Stock_Titan Posted - 1 week ago

$ORTX Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List https://www.stocktitan.net/news/ORTX/orchard-therapeutics-co-founder-and-chief-executive-officer-dr-bobby-59u5lw209b6h.html

User Image biochirp Posted - 04/18/24

$DAWN bout to pull a $ORTX ?

User Image axapol Posted - 04/13/24

@S_Franconi I’m not buying more but i I strongly believe that this company will do well on its own or partnership or buy out. They just secured enough cash until first quarter 2026 . I think the same story will happen as it did happened last year with $ORTX

User Image TrianglePlay2 Posted - 1 month ago

$ORTX did any receive cvr payment In connection with the transaction, an additional contingent value right (CVR) of $1.00 per. ADS is payable to Orchard shareholders for a total

User Image briefingcom Posted - 03/20/24

$ORTX: Orchard Therapeutics outlines U.S. launch plans for Lenmeldy, the only approved therapy for children with early-onset metachromatic leukodystrophy https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240320070726ORTX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Stock_Titan Posted - 03/20/24

$ORTX Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy https://www.stocktitan.net/news/ORTX/orchard-therapeutics-outlines-u-s-launch-plans-for-lenmeldy-80c0yly0yg4t.html

User Image AriVe Posted - 03/19/24

$ORTX a lot of respect and admiration for ORTX and the MLD foundation. Congratulations

User Image Stock_Titan Posted - 03/18/24

$ORTX Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. https://www.stocktitan.net/news/ORTX/orchard-therapeutics-receives-fda-approval-of-lenmeldy-atidarsagene-v3bq3y6neiw2.html

User Image Gurkha12345 Posted - 03/12/24

$pdsb same as my $ortx trade. Will come good.

User Image Predator777 Posted - 2 months ago

@Beanso @BatemanIam was a buyout after a RS where most people was saying that the company was a scam…all those shorts got burned. 😬 $ORTX

User Image barbaresqo Posted - 2 months ago

Was in $ORTX for years longer than I thought I’d be until we got the BO. Lot of dreams dashed on that board but ultimately long term shareholders who understood the science were rewarded.

User Image TrianglePlay2 Posted - 02/27/24

$ORTX when are they going to pay that $1 per share

User Image DonCorleone77 Posted - 3 months ago

$ORTX 2 of 2 - Orchard Therapeutics announces first patient randomized in trial of OTL-203 ...."This is a substantial milestone in the development of OTL-203 as we work toward bringing an important new treatment option to children with MPS-IH and their families," said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics. "Previously reported results from an earlier proof-of-concept study in patients showed robust metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal, ocular and auditory health demonstrating that one-time treatment with OTL-203 has the potential to positively impact a broad range of clinical manifestations not fully addressed by the current standard of care."

User Image DonCorleone77 Posted - 3 months ago

$ORTX 1 of 2 - Orchard Therapeutics announces first patient randomized in trial of OTL-203 Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (KYKOF) with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced the first patient has been randomized at the M Health Fairview Masonic Children's Hospital in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hematopoietic stem cell gene therapy, in patients with the Hurler subtype of mucopolysaccharidosis type I, MPS-IH. The trial, referred to as HURCULES, compares treatment with OTL-203 to standard of care with allogeneic hematopoietic stem cell transplant, and is expected to enroll 40 MPS-IH patients at sites across the U.S. and Europe....

User Image Stock_Titan Posted - 3 months ago

$ORTX Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome https://www.stocktitan.net/news/ORTX/orchard-therapeutics-announces-first-patient-randomized-in-ogm8rl8ymx9y.html

User Image TheMyth2020 Posted - 01/31/24

$ORTX Is this a good entry point or not really i see alot of pissed off people.

User Image Predator777 Posted - 01/28/24

$ORTX 16$ here…😡 why? And 50$ of fee…should have sold before. Was 16.70$ at the market. Why dind’t we get 17$?

User Image dalak13 Posted - 01/27/24

$ORTX PDUFA date is set for March 18 , 2024 . Maybe after that day leftover share holders will get additional $1 .

User Image TrianglePlay2 Posted - 01/27/24

$ORTX only got paid $15.90 instead of the $17. Does anyone know why?

User Image dalak13 Posted - 01/26/24

$ORTX I just get paid for my ORTX shares $16 I think it should be $17 because they get approval. Any thoughts guys ?

User Image Antun Posted - 01/25/24

$ORTX what happens with the shares that are not sold after aqusitions

User Image Last10K Posted - 01/24/24

$ORTX just filed with the SEC a Ending Agreement, a Change in Assets, a Listing Status, a Security Holders Change, a Change in Control, a Event for Officers and a Financial Exhibit https://last10k.com/sec-filings/ORTX/0001193125-24-014239.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ORTX

User Image Gurkha12345 Posted - 01/24/24

$GLTO hearing some buyout chatters. Cash heavy bio. $spy $tsla $ortx

User Image STCKPRO Posted - 01/24/24

$ORTX NEW ARTICLE : Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases https://stck.pro/news/ORTX/73652696/

User Image horshoe_azul Posted - 01/24/24

$ORTX it was a very nice ride! Congratulations to all. Wish more of my investments ended up in a similar way.

User Image tickeron Posted - 01/24/24

Wow this is a big change! $ORTX The volume increased for one day, resulting in a record-breaking daily growth of 246% of the 65-Day Volume Moving Average. View odds of downtrend. https://srnk.us/go/4977630

User Image cctranscripts Posted - 01/24/24

Notification filed by national security exchange to report the removal from listing and registr https://www.conferencecalltranscripts.org/summary/?id=12890265 $ORTX

User Image STCKPRO Posted - 01/24/24

$ORTX NEW ARTICLE : Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases https://stck.pro/news/ORTX/73652541/

User Image tradethehalt Posted - 01/23/24

$ORTX trade halt (T12) was alerted to our Members at 7:50pm EST. Halt price: $16.70 Vol: 372.35K.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
THOMAS FRANK E See Remarks See Remarks Mar 10 Option 0.4591 20,000 9,182 92,081 03/14/23
THOMAS FRANK E See Remarks See Remarks Feb 09 Option 0.4591 20,000 9,182 72,081 02/13/23